GM1 Gangliosidosis Pre-Clinical Publication

We believe that intracerebroventricular enzyme replacement therapy holds exciting potential to treat rare pediatric neurological diseases, including GM1 Gangliosidosis, which is in our pre-clinical development pipeline (AX 552).

Download Intracerebroventricular enzyme replacement therapy with β-galactosidase reverses brain pathologies due to GM1 gangliosidosis in mice, published in The Journal of Biological Chemistry (2020)

Related Posts

See All

Tralesinidase Alfa Pre-Clinical Publications

Allievex obtained an exclusive worldwide license for tralesinidase alfa from BioMarin (BMN 250) in October 2019 for the treatment of patients with Sanfilippo syndrome type B. Review pre-clinical publi

Screen Shot 2021-01-25 at 4.58.05 PM.png